YOU ARE HERE: LAT HomeCollectionsGeneric Brands

Generic Brands

May 20, 2006 | Daniel Yi, Times Staff Writer
The nation's largest pharmacy benefits manager announced Friday that it was distributing more generic drugs than brand-name counterparts, a sign that costly brand-name prescription medicines may be losing their grip on the market, leading to lower drug costs for consumers. The trend is significant because even more generic prescription drugs are expected to hit the market in the near future.
March 7, 2006 | From Bloomberg News
GlaxoSmithKline lost a bid to prevent sales of generic versions of its $900-million-a-year allergy drug Flonase. Boehringer Ingelheim's generic version could reach the market today after U.S. District Judge Andre Davis in Baltimore refused to block sales while Glaxo pursues a lawsuit against the Food and Drug Administration.
January 4, 2006 | From Bloomberg News
Allergan Inc. said it won a ruling temporarily blocking Apotex Inc. from making or selling a generic version of a treatment for eye inflammation. The ruling, issued Dec. 29 by U.S. District Judge Martin Jenkins in San Francisco, temporarily prohibits Apotex from manufacturing or selling a generic version of Allergan's Acular in the U.S., Allergan spokeswoman Caroline Van Hove said. Irvine-based Allergan, which also makes the anti-wrinkle drug Botox, sued Apotex over patents for Acular in 2001.
September 7, 2005 | From Associated Press
Barr Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. said they would cooperate in launching generic versions of Sanofi-Aventis' Allegra allergy drug. Barr of Pomona, N.Y., received final approval last week for the generic drug from the Food and Drug Administration. Allegra sales were worth $1.4 billion for the 12 months ended in June, according to research firm IMS Health.
August 24, 2005 | From Bloomberg News
Generic-drug makers including Ivax Corp. and Teva Pharmaceutical Industries Ltd. aren't infringing patents on Pfizer Inc.'s epilepsy drug Neurontin by selling low-cost versions, a federal judge ruled. U.S. District Judge John Lifland in Newark, N.J., said the generic version of gabapentin, the key ingredient in Neurontin, didn't infringe. Pfizer will appeal, spokesman Paul Fitzhenry said. Teva, Ivax and Alpharma Inc.
August 9, 2005 | Ricardo Alonso-Zaldivar, Times Staff Writer
Mabel Stoltz, at 93, lives independently in her own home in a quiet harbor town on the Minnesota shore of Lake Superior. But she has to watch her budget carefully and has been buying prescription drugs from Canada. So Stoltz was surprised to learn recently that she could buy her generic-label medications for much less from a U.S. pharmacy -- a potential savings of $560 a year for two prescriptions.
June 7, 2005 | From Bloomberg News
Pfizer Inc. and other drug companies have the right to sell unbranded versions of their own drugs even if they undercut sales of generic competitors, a U.S. appeals court has ruled. Teva Pharmaceutical Industries Ltd., the world's biggest generic-drug maker, sued in August to stop Pfizer from selling a lower-cost version of the epilepsy drug Neurontin. The U.S. Court of Appeals for the District of Columbia Circuit, in a ruling Friday, said the law didn't prohibit such "authorized generics."
April 15, 2005 | From Associated Press
A federal judge Thursday turned away the claims of generic drug manufacturers and ruled valid a patent for Eli Lilly & Co.'s drug Zyprexa. U.S. District Judge Richard Young in Indianapolis ruled in favor of Lilly on all of the matters in dispute in the case, Lilly said. However, appeals are likely. The ruling is a huge relief to Lilly, Chief Executive Sidney Taurel said.
January 22, 2005 | From Bloomberg News
Allergan Inc., the maker of Botox, said Friday that a federal court dismissed the company's lawsuit seeking to win reclassification of its Restasis treatment for dry eyes, which would have prevented the sale of a generic version for three years. The U.S. District Court in Washington agreed with the Food and Drug Administration's classification of Restasis as an antibiotic, according to court papers.
August 31, 2004 | From Reuters
Mylan Laboratories Inc. said it had withdrawn a lawsuit against the Food and Drug Administration concerning deals involving the makers of brand-name and generic drugs, but said it might refile the suit with additional complaints. Mylan sued the FDA in early July to protest the agency's support for a practice by some pharmaceutical companies to authorize a generic drug company to sell a version of a particular brand-name drug.
Los Angeles Times Articles